Jagsonpal Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹64Cr
- +8.5% YoY
- −12.3% QoQ
- Net profit
- ₹9Cr
- +28.6% YoY
- −18.2% QoQ
- Margin
- 17%
- +2 pp YoY
- −5 pp QoQ
Guidance rank: #54 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Jagsonpal Pharmaceuticals targets organic growth at approximately 1.5x the Indian Pharma Market (IPM) growth, aiming for 12%-15% revenue growth. Jagsonpal aims to sustain and accelerate growth momentum, targeting 1.5x the Indian Pharma Market (IPM) growth (currently 6%-9%), implying 12%-15% revenue growth.
From Jagsonpal Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Jagsonpal Pharmaceuticals targets organic growth at approximately 1.5x the Indian Pharma Market (IPM) growth, aiming for 12%-15% revenue growth.
- Volume growth for FY26 was 2% for Jagsonpal, slightly higher than the market's ~1%.
- New product launches contribute around 3.2% to growth, matching or exceeding industry averages.
- Price growth is around 6%-7%, which is higher than the IPM price growth (~4.8%-5%).
- Focus on strong therapeutic areas: Gynaecology (about 50% of business), Orthopedics (~25%), and Dermatology (10%-15%), with growth led mainly by Gynaec and Derma.
- Enhancing MR productivity and training to increase sales efficiency without increasing headcount.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Jagsonpal Pharmaceuticals Limited does not require additional capital for organic growth, as growth is driven by better execution and field force productivity rather than capital-intensive investments.
- Current capital expenditure is focused on maintaining existing operations and organic business growth.
- Any capital deployment of real cash will be primarily for inorganic strategies, such as acquisitions.
- The company has adequate cash (~INR190 crores) and access to bank finance, making it capable of funding acquisitions up to INR400 crores without stressing the balance sheet.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Jagsonpal Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Jagsonpal Pharmaceuticals Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 64 | 59 | +8.5% | 73 | -12.3% |
| Operating profit (EBITDA) | 11 | 9 | +22.2% | 16 | -31.2% |
| Operating margin | 17% | 15% | +2 pp | 22% | -5 pp |
| Profit before tax | 12 | 9 | +33.3% | 15 | -20% |
| Net profit (PAT) | 9 | 7 | +28.6% | 11 | -18.2% |
| EPS (₹) | 1.31 | 0.99 | +32.3% | 1.64 | -20.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹81 Cr, net profit ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jagsonpal Pharma's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q4 FY26 results?
Jagsonpal Pharmaceuticals targets organic growth at approximately 1.5x the Indian Pharma Market (IPM) growth, aiming for 12%-15% revenue growth. Jagsonpal aims to sustain and accelerate growth momentum, targeting 1.5x the Indian Pharma Market (IPM) growth (currently 6%-9%), implying 12%-15% revenue growth.
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
Jagsonpal Pharmaceuticals Limited does not require additional capital for organic growth, as growth is driven by better execution and field force productivity rather than capital-intensive investments.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
